Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
USMCA Talks Set to Resume as Mexico Signals New Round of Trade Negotiations 
Asian Stocks Rise as Tech Gains Offset US-Iran Tensions, Oil Prices Add Pressure 
DOJ Launches Antitrust Investigation Into the NFL Over Broadcast Restrictions 
NASA Resumes Cygnus XL Cargo Docking with Space Station After Software Fix 
U.S. Disrupts Russian Military Hackers' Global DNS Hijacking Network 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
US Dollar Slips Amid Iran Tensions and Fed Leadership Uncertainty 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
South Korea Central Bank Signals Cautious Policy Amid Inflation and Middle East Tensions 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
U.S. Officials Express Optimism Over New CDC Director Selection Amid Vaccine Policy Turmoil 
Asian Currencies Stay Range-Bound as Dollar Holds Steady Ahead of Fed Nominee Hearing 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
The Seoul Central District Court had ruled that Medytox's patents for botulinum toxin (botox) strains and manufacturing process were stolen by Daewoong Pharmaceutical in developing Nabota.
Thus, the court prohibited Daewoong from manufacturing and selling its botox products, ordering that those that have already been produced should be discarded.
It also ordered Daewoong to pay 40 billion won in damages to Medytox, the first Korean company to succeed in mass-producing botox strains.
Medytox sued Daewoong in 2017, accusing it of stealing its botox strain and manufacturing process.
Daewoong claimed that it found its botox strain in a barn in Gyeonggi Province.
Medytox vowed to continue to protect its patent, while Daewoong said it would appeal the ruling.
The US International Trade Commission (USITC) had earlier ruled in favor of Medytox in December 2020 and ordered a 21-month import ban on Daewoong's products into the US. Daewoong also agreed to pay royalties to Medytox to settle the dispute shortly after the USITC decision.
